Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation

Neurology

Volumn 47, Issue 6, 1996, Pages 1493-1495

  Pappert, E J ^a   Goetz, C G ^a   Niederman, F ^a   Ling, Z D ^a   Stebbins, G T ^a   Carvey, P M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DYSKINESIA; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MALE; MOTOR PERFORMANCE; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PHYSICAL DISABILITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0029732865     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.6.1493     Document Type: Article

References (14)

1. Fahn S. "On-off" phenomenon with levodopa therapy in parkinsonism. Neurology 1974;24:431-441.
2. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 1988;24: 366-371.
3. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanism, part II. Ann Neurol 1988;24: 372-378.
4. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. "On-off" phenomenon in Parkinson's disease: relationship to L-dopa absorption and transport. N Engl J Med 1984;310:483-488.
5. Sage JI, McHale DM, Sonsalla P, Vitagliano D, Heikkila RE. Continuous levodopa infusions to treat complex dystonia in Parkinson's disease. Neurology 1989;39:888-891.
6. Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with "on-off" fluctuations. Neurology 1993;43:1698-1703.
7. Pappert EJ, Buhrfiend C, Lipton JW, Carvey PM, Stebbins GT, Goetz CG. Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use. Mov Disord 1996;11:24-26.
8. Kurth MC, Tetrud JW, Irwin I, Lyness WH, Langston JW. Oral levodopa/carbidopa solution versus tablets in Parkinson's disease patients with severe fluctuations: a pilot study. Neurology 1993;43:1036-1039.
9. Singh A, Tanner CM, Wasserstein P, Kurth M, Tetrud J. Orally administered levodopa-carbidopa (LD-CD) solution reduces "off-time" in Parkinson's disease [abstract]. Neurology 1993;43:A197.
10. Verhagen Metman L, Hoff J, Mouradian MM, Chase TN. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord 1994;9:463-465.
11. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994;9:390-394.
12. Wagner J, Vitali P, Palfreyman MG, Zraika M, Huot S. Simultaneous determination of 3,4-dihydroxyphenylalanine, 5-hydroxytryptophan, dopamine, 4-hydroxy-3-methoxyphenylalanine, norepinephrine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, serotonin, and 5-hydroxyindoleacetic acid in rat cerebrospinal fluid and brain by high-performance liquid chromatography with electrochemical detection. J Neurochem 1982;38:1241-1254.
13. Rondot P, Ziegler M, Aymard N, Teinturier A. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease. Neurology 1989;39(suppl 2): 74-77.
14. Deleu D, Jacques M, Michotte Y, Ebinger G. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. Neurology 1989;39(suppl 2):88-92.